Skip to main content

Advertisement

Log in

Specific cytotoxic T lymphocytes in gene therapy

  • REVIEW
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

 Cytotoxic T lymphocytes possess the capacity to lyse target cells which express antigens on their surface recognized by the T cell receptor. These cells are crucial in the body’s defense against foreign antigens. It has long been a goal of tumor biology to utilize T cells, specialized in the elimination of unwanted cells, for the treatment of cancer. The killing activity of T lymphocytes is restricted to specific antigen-presenting cells. For this reason the use of cytotoxic T cells in the elimination of cancer cells is limited to cancer cells which present neoantigens on their surface. To circumvent this limitation we describe a procedure in which the ζ component of the T cell receptor is genetically manipulated and equipped with an extracellular recognition domain. Introduction of a chimeric gene, consisting of the ζ chain of the T cell receptor and a single-chain antibody domain, into cytotoxic T lymphocytes results in T cells with a predetermined recognition specificity for particular tumor cells. The MHC restriction of target cell recognition can be avoided and tumor cells recognized by the single chain antibody domain can be recognized and lysed. Retroviral-mediated gene transduction was used to introduce chimeric ζ chain constructs into primary T cells of mice. The cocultivation of retrovirus producing helper cells with in vitro activated T lymphocytes led to a high gene transduction efficiency into primary T cells. These primary T cells assumed a predetermined specificity for target cell recognition and lysis. The production and provision of tumor cell specific T lymphocytes might not be sufficient to eradicate large tumors in vivo. Using a Schwannoma cell line, we showed that transplanted tumors secrete transforming growth factor β and thereby stifle the action of lymphocytes. We suggest that a coordinated strategy including the suppression of tumor cells specific antilymphocyte action and the provision of tumor cell specific T cells might be required to successfully eliminate tumor cells in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 13 September 1996 / Accepted: 30 October 1996

Rights and permissions

Reprints and permissions

About this article

Cite this article

Altenschmidt, U., Moritz, D. & Groner, B. Specific cytotoxic T lymphocytes in gene therapy. J Mol Med 75, 259–266 (1997). https://doi.org/10.1007/s001090050111

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s001090050111

Navigation